JP7840865B2 - キメラ抗原受容体ターゲティングｃｄ３３ - Google Patents

キメラ抗原受容体ターゲティングｃｄ３３

Info

Publication number
JP7840865B2
JP7840865B2 JP2022559600A JP2022559600A JP7840865B2 JP 7840865 B2 JP7840865 B2 JP 7840865B2 JP 2022559600 A JP2022559600 A JP 2022559600A JP 2022559600 A JP2022559600 A JP 2022559600A JP 7840865 B2 JP7840865 B2 JP 7840865B2
Authority
JP
Japan
Prior art keywords
seq
scfv
containing seq
sequence
coding sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022559600A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023520409A (ja
JP2023520409A5 (enExample
Inventor
タートル，キャメロン・ジェイ
ウォルター，ローランド・ビー
ラースロー，ジョージ・エス
フィオレンツァ，サルバトーレ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fred Hutchinson Cancer Center
Original Assignee
Fred Hutchinson Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fred Hutchinson Cancer Center filed Critical Fred Hutchinson Cancer Center
Publication of JP2023520409A publication Critical patent/JP2023520409A/ja
Publication of JP2023520409A5 publication Critical patent/JP2023520409A5/ja
Priority to JP2026050913A priority Critical patent/JP2026108769A/ja
Application granted granted Critical
Publication of JP7840865B2 publication Critical patent/JP7840865B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/23—On/off switch
    • A61K2239/25—Suicide switch
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2022559600A 2020-03-31 2021-03-31 キメラ抗原受容体ターゲティングｃｄ３３ Active JP7840865B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026050913A JP2026108769A (ja) 2020-03-31 2026-03-25 キメラ抗原受容体ターゲティングｃｄ３３

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063003196P 2020-03-31 2020-03-31
US63/003,196 2020-03-31
PCT/US2021/025255 WO2021202799A2 (en) 2020-03-31 2021-03-31 Chimeric antigen receptors targeting cd33

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026050913A Division JP2026108769A (ja) 2020-03-31 2026-03-25 キメラ抗原受容体ターゲティングｃｄ３３

Publications (3)

Publication Number Publication Date
JP2023520409A JP2023520409A (ja) 2023-05-17
JP2023520409A5 JP2023520409A5 (enExample) 2024-03-29
JP7840865B2 true JP7840865B2 (ja) 2026-04-06

Family

ID=77929997

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022559600A Active JP7840865B2 (ja) 2020-03-31 2021-03-31 キメラ抗原受容体ターゲティングｃｄ３３
JP2026050913A Pending JP2026108769A (ja) 2020-03-31 2026-03-25 キメラ抗原受容体ターゲティングｃｄ３３

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026050913A Pending JP2026108769A (ja) 2020-03-31 2026-03-25 キメラ抗原受容体ターゲティングｃｄ３３

Country Status (6)

Country Link
US (2) US12570758B2 (enExample)
EP (1) EP4126959A4 (enExample)
JP (2) JP7840865B2 (enExample)
CN (1) CN115348973A (enExample)
CA (1) CA3172691A1 (enExample)
WO (1) WO2021202799A2 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022386336A1 (en) * 2021-11-10 2024-05-16 The Trustees Of The University Of Pennsylvania Engineered chimeric antigen receptor (car) microglia-like cells for the treatment of neurodegenerative disorders

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170145094A1 (en) 2014-04-03 2017-05-25 Cellectis Cd33 specific chimeric antigen receptors for cancer immunotherapy
WO2018175988A1 (en) 2017-03-24 2018-09-27 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-cd33 immunotherapy
WO2018211245A1 (en) 2017-05-15 2018-11-22 Autolus Limited Cell
JP2020509050A (ja) 2017-02-28 2020-03-26 ブイオーアール バイオファーマ, インコーポレーテッドVor Biopharma, Inc. 系統特異的タンパク質の阻害のための組成物および方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008045962A2 (en) * 2006-10-10 2008-04-17 Mayo Foundation For Medical Education And Research Methods and materials related to anti-a (beta) antibodies
EP2814846B1 (en) 2012-02-13 2020-01-08 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
AR097648A1 (es) 2013-09-13 2016-04-06 Amgen Inc Combinación de factores epigenéticos y compuestos biespecíficos que tienen como diana cd33 y cd3 en el tratamiento de leucemia mieloide
JP6831777B2 (ja) * 2014-07-21 2021-02-17 ノバルティス アーゲー Ｃｄ３３キメラ抗原受容体を使用する癌の処置
GB201514875D0 (en) 2015-08-20 2015-10-07 Autolus Ltd Receptor
GB201518136D0 (en) 2015-10-14 2015-11-25 Glaxosmithkline Ip Dev Ltd Novel chimeric antigen receptors
JP7189019B2 (ja) 2016-02-05 2022-12-13 シティ・オブ・ホープ 中枢神経系の癌の治療のための操作されたｔ細胞の投与
CN118652336A (zh) * 2016-06-08 2024-09-17 普瑞赛格恩公司 Cd33特异性嵌合抗原受体
US20190233534A1 (en) 2016-07-14 2019-08-01 Fred Hutchinson Cancer Research Center Multiple bi-specific binding domain constructs with different epitope binding to treat cancer
WO2018218207A1 (en) 2017-05-26 2018-11-29 Fred Hutchinson Cancer Research Center Anti-cd33 antibodies and uses thereof
WO2019084234A1 (en) 2017-10-26 2019-05-02 St. Jude Childen's Research Hospital, Inc. METHODS AND COMPOSITIONS FOR TREATING CD33 + CANCERS AND IMPROVING IN VIVO PERSISTENCE OF CHIMERIC ANTIGEN RECEPTOR T CELLS
US20210017277A1 (en) 2018-03-14 2021-01-21 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Anti-cd33 chimeric antigen receptors and their uses
JOP20190116A1 (ar) 2018-05-24 2019-11-24 Janssen Biotech Inc الأجسام المضادة لتكتل التمايز 33 (cd33)، والأجسام المضادة ثنائية النوعية لتكتل التمايز 33 (cd33)/تكتل التمايز 3 (cd3) واستخداماتها
WO2019246593A2 (en) 2018-06-22 2019-12-26 Fred Hutchinson Cancer Research Center Compositions and methods to target cll-1 and cd123 for the treatment of acute myeloid leukemia and related disorders
EP4126248A4 (en) * 2020-03-31 2024-07-10 Fred Hutchinson Cancer Center HUMAN ANTI-CD33 ANTIBODIES AND THEIR USES
EP4126925A4 (en) 2020-03-31 2024-07-24 Fred Hutchinson Cancer Center CHIMERIC ANTIGEN RECEPTORS TARGETED AGAINST CD33

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170145094A1 (en) 2014-04-03 2017-05-25 Cellectis Cd33 specific chimeric antigen receptors for cancer immunotherapy
JP2020509050A (ja) 2017-02-28 2020-03-26 ブイオーアール バイオファーマ, インコーポレーテッドVor Biopharma, Inc. 系統特異的タンパク質の阻害のための組成物および方法
WO2018175988A1 (en) 2017-03-24 2018-09-27 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-cd33 immunotherapy
WO2018211245A1 (en) 2017-05-15 2018-11-22 Autolus Limited Cell

Also Published As

Publication number Publication date
CA3172691A1 (en) 2021-10-07
US12570758B2 (en) 2026-03-10
JP2026108769A (ja) 2026-06-30
WO2021202799A2 (en) 2021-10-07
EP4126959A4 (en) 2024-05-08
JP2023520409A (ja) 2023-05-17
US20230220103A1 (en) 2023-07-13
WO2021202799A3 (en) 2021-11-11
US20260167738A1 (en) 2026-06-18
CN115348973A (zh) 2022-11-15
EP4126959A2 (en) 2023-02-08

Similar Documents

Publication Publication Date Title
JP6985934B2 (ja) 操作された造血幹細胞／前駆細胞及び非ｔエフェクター細胞、ならびにその使用
JP7859985B2 (ja) Ｃｄ３３を標的にするキメラ抗原受容体
JP7855521B2 (ja) ヒト抗ｃｄ３３抗体及びその使用
WO2019246593A2 (en) Compositions and methods to target cll-1 and cd123 for the treatment of acute myeloid leukemia and related disorders
CA2861491A1 (en) Bispecific chimeric antigen receptors and therapeutic uses thereof
US12351618B2 (en) Engineered trimeric CD70 proteins and uses thereof
US20250144139A1 (en) Chimeric antigen receptors binding steap1
JP2022526187A (ja) 造血細胞の細胞傷害性を促進するための組成物及び方法
WO2021202726A2 (en) Anti-cd33 antibodies and uses thereof
US20230218669A1 (en) Augmenting antigen-negative cell death in antigen-targeted immunotherapies
JP2026513651A (ja) Ａｄｇｒｅ２キメラ受容体ｎｋ細胞組成物及び使用方法
US12570758B2 (en) Chimeric antigen receptors targeting CD33
US20240091260A1 (en) Chimeric antigen receptors that bind preferentially expressed antigen in melanoma (prame)/hla-a2 to treat cancer
US20250025557A1 (en) Treatments for cancers utilizing cell-targeted therapies and associated research protocols
WO2025207642A1 (en) Cxcr3 isoforms to improve recombinant receptor trafficking
WO2024254515A2 (en) Systems and methods to direct cellular therapies in vivo to an organ
AU2024274301A1 (en) Pro-inflammatory cytokine enhanced steap1 recombinant receptors
WO2025125610A1 (en) Chimeric antigen receptor directed against the chemokine receptor ccr7
JP2026503849A (ja) 免疫細胞の機能を増強するための誘導型サイトカイン導入遺伝子

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240318

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240318

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250520

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250815

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250930

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251222

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260224

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260325

R150 Certificate of patent or registration of utility model

Ref document number: 7840865

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150